Clinical characteristics of patients with SLE divided according to the presence or absence of serum anti-β2GPI peptide IgG immunoreactivity
| Characteristic . | Patients with serum anti-β2GPI peptide Abs . | Patients without serum anti-β2GPI peptide Abs . |
|---|---|---|
| Patients with SLE, n | 22 | 22 |
| Sex, M/F | 3/19 | 3/19 |
| Median age, y (range) | 35 (22-66) | 39 (19-54) |
| Median disease duration, y (range) | 8 (0.3-23.6) | 8 (0.5-23) |
| Arthritis, n (%) | 19 (86.4) | 15 (68.2) |
| Cutaneous manifestations, n (%) | 12 (54.5) | 16 (72.7) |
| Serositis, n (%) | 6 (27.3) | 6 (27.3) |
| Cytopenia, n (%) | 16 (72.7) | 17 (77.3) |
| Renal manifestations, n (%) | 5 (22.7) | 8 (36.4) |
| Neuropsychiatric manifestations, n (%) | 10 (45.5) | 12 (54.5) |
| Arterial thrombosis, n (%) | 0 (0) | 0 (0) |
| Venous thrombosis, n (%) | 0 (0) | 2 (9.1) |
| Pregnancy morbidity, n (%) | 0 (0) | 0 (0) |
| Anti-β2GPI IgG, n (%) | 5 (22.7) | 8 (36.4) |
| Anti-cardiolipin CL+β2GPI IgG, n (%) | 4 (18.2) | 8 (36.4) |
| Characteristic . | Patients with serum anti-β2GPI peptide Abs . | Patients without serum anti-β2GPI peptide Abs . |
|---|---|---|
| Patients with SLE, n | 22 | 22 |
| Sex, M/F | 3/19 | 3/19 |
| Median age, y (range) | 35 (22-66) | 39 (19-54) |
| Median disease duration, y (range) | 8 (0.3-23.6) | 8 (0.5-23) |
| Arthritis, n (%) | 19 (86.4) | 15 (68.2) |
| Cutaneous manifestations, n (%) | 12 (54.5) | 16 (72.7) |
| Serositis, n (%) | 6 (27.3) | 6 (27.3) |
| Cytopenia, n (%) | 16 (72.7) | 17 (77.3) |
| Renal manifestations, n (%) | 5 (22.7) | 8 (36.4) |
| Neuropsychiatric manifestations, n (%) | 10 (45.5) | 12 (54.5) |
| Arterial thrombosis, n (%) | 0 (0) | 0 (0) |
| Venous thrombosis, n (%) | 0 (0) | 2 (9.1) |
| Pregnancy morbidity, n (%) | 0 (0) | 0 (0) |
| Anti-β2GPI IgG, n (%) | 5 (22.7) | 8 (36.4) |
| Anti-cardiolipin CL+β2GPI IgG, n (%) | 4 (18.2) | 8 (36.4) |